The case for & against
Bull & Bear analysis
Bearish
Direct Corporation (NASDAQ: DIRC) specializes in the biopharmaceutical industry, focusing on developing innovative therapies for alcohol-associated hepatitis (AH). The company’s lead candidate, larcicosterol, is positioned to meet the critical unmet need within this therapeutic area, where effective treatments are currently lacking. Through its strategic initiatives and pioneering approach, Direct aims to transform the treatment landscape for AH, which has significant mortality rates and various costs associated with hospitalization in the U.S.
Bull says
- ↑Phase 2B trial delivered 60% 90-day mortality reduction in AH patients
- ↑Breakthrough Therapy status accelerates FDA review and development path
- ↑AH market spans 160k hospitalizations and ~$10 B in annual costs
- ↑Q2 R&D expenses cut to $2.2 M from $7.9 M YoY
- ↑Medical community support may enable rapid uptake post-approval
- ↑Cash runway extends into Q3 2025 with $12 M on hand
Bear says
- ↓2024 revenue dropped to $2 M from $2.6 M in 2023
- ↓Q2 2024 cash burn reached $5.8 M, raising solvency concerns
- ↓Phase 3 needs $20–25 M financing, risking timeline if delayed
- ↓Market adoption may lag due to low AH awareness
- ↓Phase 3 efficacy risk could sharply impact valuation if fails
- ↓Leverage risk elevated amid thin revenue streams
Earnings Call · Q4 2023 · Mgmt. Guidance
Updated 09-05-2026neutral
Transcript signals
Bull points
- The key takeaway from these results is that patients treated with Lercucosterol had lower mortality at 90 days compared with patients that received placebo.
- believe they show the potential for Lercucosterol to provide a clinically meaningful survival benefit in these severe AH patients.
- We continue to believe that the affirmed data provide compelling evidence that Lorsucosterol could represent a safe and effective therapy with life-saving potential for AH patients.
Bear points
- Total revenues in 2023 were $8.5 million compared to $19.3 million in 2022.
- 2023 revenues were lower primarily because 2022 revenues included $10 million of milestone payments related to our POSIMR agreement with INICOL.
- For the fourth quarter of 2023, revenues were 2.7 million compared to 3.3 million for the prior year.
Read full transcript analysis ›